Normal Alpha-1-Antitrypsin Variants Display in Serum Allele-Specific Protein Levels

Overview

Journal J Proteome Res

Publisher American Chemical Society

Specialty Biochemistry

Date 2023 Mar 22

PMID 36946534

Authors

Shelley Jager

Dario A T Cramer

Albert J R Heck

Affiliations

Soon will be listed here.

Abstract

Alpha-1-antitrypsin (A1AT or SERPINA1) has been proposed as a putative biomarker distinguishing healthy from diseased donors throughout several proteomics studies. However, the SERPINA1 gene displays high variability of frequent occurring genotypes among the general population. These different genotypes may affect A1AT expression and serum protein concentrations, and this is often not known, ignored, and/or not reported in serum proteomics studies. Here, we address allele-specific protein serum levels of A1AT in donors carrying the normal M variants of A1AT by measuring the proteoform profiles of purified A1AT from 81 serum samples, originating from 52 donors. When focusing on heterozygous donors, our data clearly reveal a statistically relevant difference in allele-specific protein serum levels of A1AT. In donors with genotype PI*M1VM1A, the experimentally observed ratio was approximately 1:1 (M1V/M1A, 1.00:0.96 ± 0.07, = 17). For individuals with genotype PI*M1VM2, this ratio was 1:1.28 (M1V/M2, 1.00:1.31, ±0.19, = 7). For genotypes PI*M1VM3 and PI*M1AM3, a significant higher amount of M3 was observed compared to the M1-subtypes (M1V/M3, 1.00:1.84 ± 0.35, = 8; M1A/M3, 1.00:1.61 ± 0.33, = 5). We argue that these observations are important and should be considered when analyzing serum A1AT levels before proposing A1AT as a putative serum biomarker.

References

Cramer D, Franc V, Caval T, Heck A . Charting the Proteoform Landscape of Serum Proteins in Individual Donors by High-Resolution Native Mass Spectrometry. Anal Chem. 2022; 94(37):12732-12741. PMC: 9494300. DOI: 10.1021/acs.analchem.2c02215. View

Graham A, Hayes K, Weidinger S, Newton C, Markham A, Kalsheker N . Characterisation of the alpha-1-antitrypsin M3 gene, a normal variant. Hum Genet. 1990; 85(3):381-2. DOI: 10.1007/BF00206766. View

McCarthy C, Saldova R, Wormald M, Rudd P, McElvaney N, Reeves E . The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions. J Proteome Res. 2014; 13(7):3131-43. DOI: 10.1021/pr500146y. View

Shi J, Wang X, Zhu H, Jiang H, Wang D, Nesvizhskii A . Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method. J Proteome Res. 2018; 17(10):3606-3612. PMC: 6309561. DOI: 10.1021/acs.jproteome.8b00620. View

Kolarich D, Turecek P, Weber A, Mitterer A, Graninger M, Matthiessen P . Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy. Transfusion. 2006; 46(11):1959-77. DOI: 10.1111/j.1537-2995.2006.01004.x. View

Li M, Ren R, Yan M, Chen S, Chen C, Yan J . Identification of novel biomarkers for sepsis diagnosis via serum proteomic analysis using iTRAQ-2D-LC-MS/MS. J Clin Lab Anal. 2021; 36(1):e24142. PMC: 8761403. DOI: 10.1002/jcla.24142. View

Nukiwa T, Brantly M, OGUSHI F, Fells G, Crystal R . Characterization of the gene and protein of the common alpha 1-antitrypsin normal M2 allele. Am J Hum Genet. 1988; 43(3):322-30. PMC: 1715372. View

Yan H, Yuan W, Velculescu V, Vogelstein B, Kinzler K . Allelic variation in human gene expression. Science. 2002; 297(5584):1143. DOI: 10.1126/science.1072545. View

Wu D, Guo M, Robinson C . Connecting single-nucleotide polymorphisms, glycosylation status, and interactions of plasma serine protease inhibitors. Chem. 2024; 9(3):665-681. PMC: 10914678. DOI: 10.1016/j.chempr.2022.11.018. View

10.

Pervakova M, Emanuel V, Titova O, Lapin S, Mazurov V, Belyaeva I . The Diagnostic Value of Alpha-1-Antitrypsin Phenotype in Patients with Granulomatosis with Polyangiitis. Int J Rheumatol. 2016; 2016:7831410. PMC: 4835640. DOI: 10.1155/2016/7831410. View

11.

Ruhaak L, Uh H, Deelder A, Dolhain R, Wuhrer M . Total plasma N-glycome changes during pregnancy. J Proteome Res. 2014; 13(3):1657-68. DOI: 10.1021/pr401128j. View

12.

Mondal G, Saroha A, Bose P, Chatterjee B . Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients. Glycoconj J. 2016; 33(2):209-18. DOI: 10.1007/s10719-016-9658-2. View

13.

Lewis E . Expanding the clinical indications for α(1)-antitrypsin therapy. Mol Med. 2012; 18:957-70. PMC: 3459478. DOI: 10.2119/molmed.2011.00196. View

14.

Huang X, Zheng Y, Zhang F, Wei Z, Wang Y, Carrell R . Molecular Mechanism of Z α1-Antitrypsin Deficiency. J Biol Chem. 2016; 291(30):15674-86. PMC: 4957051. DOI: 10.1074/jbc.M116.727826. View

15.

Curiel D, Chytil A, Courtney M, Crystal R . Serum alpha 1-antitrypsin deficiency associated with the common S-type (Glu264----Val) mutation results from intracellular degradation of alpha 1-antitrypsin prior to secretion. J Biol Chem. 1989; 264(18):10477-86. View

16.

Bergin D, Reeves E, Meleady P, Henry M, McElvaney O, Carroll T . α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest. 2010; 120(12):4236-50. PMC: 2993580. DOI: 10.1172/JCI41196. View

17.

Zorzetto M, Russi E, Senn O, Imboden M, Ferrarotti I, Tinelli C . SERPINA1 gene variants in individuals from the general population with reduced alpha1-antitrypsin concentrations. Clin Chem. 2008; 54(8):1331-8. DOI: 10.1373/clinchem.2007.102798. View

18.

M Greene C, Marciniak S, Teckman J, Ferrarotti I, Brantly M, Lomas D . α1-Antitrypsin deficiency. Nat Rev Dis Primers. 2016; 2:16051. DOI: 10.1038/nrdp.2016.51. View

19.

Hou J, Wang X, McShane E, Zauber H, Sun W, Selbach M . Extensive allele-specific translational regulation in hybrid mice. Mol Syst Biol. 2015; 11(8):825. PMC: 4562498. DOI: 10.15252/msb.156240. View

20.

Guttman O, Baranovski B, Schuster R, Kaner Z, Freixo-Lima G, Bahar N . Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats. Clin Exp Immunol. 2014; 179(2):161-72. PMC: 4298394. DOI: 10.1111/cei.12476. View